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OBESITY, WEIGHT CHANGE AND DISEASE ACTIVITY MEASURES IN 
PATIENTS WITH RHEUMATOID ARTHRITIS 
 
 
DAVID JOSEPH KREPS 
 
 
ABSTRACT 
Background: Rheumatoid arthritis (RA) is an autoimmune disease that causes 
inflammatory polyarthritis, typically of the small joints. Obesity, a serious global 
epidemic, has been shown to increase systemic inflammatory biomarkers, 
several of which are related to RA pathophysiology. Associations have been 
observed between obesity and worsened RA disease activity outcomes in cross-
sectional studies. Limited longitudinal studies investigated the effects of weight 
change on RA disease activity measures. Surgical interventions for weight loss in 
RA patients showed marked improvement in RA disease activity measures and 
outcomes but typical weight change in a clinical setting has not been 
investigated.  
Objective: To investigate the impact of typical weight change on RA disease 
activity measures.  
Methods: We conducted a retrospective cohort study on 178 RA patients seen in 
typical clinical practice that met the inclusion criteria for the study, which included 
patients with a minimum of two clinical disease activity assessments (CDAI) with 
corresponding body mass index (BMI) measures. Medical record review was 
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conducted for each clinic visit where CDAI and BMI were measured, and at each 
of these visits, sociodemographic, lifestyle, medication usage, questionnaire 
data, RA characteristics, laboratory values, and comorbidities were collected. 
Linear regression was used to analyze the association between ΔBMI and 
ΔCDAI, defined at the dates of minimum and maximum BMI for each subject, 
adjusting for confounders including sex, age, disease duration, smoking status, 
serologic status, and steroid usage. Logistic regression was performed to 
evaluate whether ΔBMI was associated with low/remission RA disease activity 
according to accepted CDAI cutoffs.  
Results: Unadjusted linear regression was performed on all 178 subjects to 
analyze the overall trend within the sample population. For every 1 kg/m2 
increase in BMI, CDAI increased by 0.49 points, but these results were not 
statistically significant (p=0.155, 95%CI -0.176, 1.097). Subjects were stratified 
into BMI gain, stable, and loss groups. Within the BMI loss group (defined as 
those whose BMI decreased by more than 1 kg/m2), a significant association was 
found with ΔCDAI (β= -2.61 [p=0.028, 95%CI -4.91, -0.298]). Unadjusted linear 
regression on the BMI gain and stable groups was found to be not statistically 
significant. This association remained significant after adjusting for sex, age, 
disease duration, smoking status, serologic status, and steroid usage (β=-2.499 
[p=0.044, 95%CI -4.94, -0.061]). There was no association between ΔBMI and 
low/remission RA disease activity (OR 0.990, (95%CI 0.855, 1.146). When 
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stratified by BMI gain, stable, and loss groups there was no significant 
association with low/remission RA disease activity.  
Conclusion: These results suggest that weight loss may be associated with 
improved disease activity among patients with RA seen in a typical clinical 
setting. Weight loss has the potential to be a non-pharmacologic intervention to 
improve RA disease activity. Prospective studies of weight loss and RA disease 
activity are necessary to replicate these results.  
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INTRODUCTION 
  Rheumatoid arthritis (RA) is a disease currently affecting 1.5 million 
Americans, with 41 out of 100,000 people developing the disease annually [1]. 
RA accounts for 22% of all the deaths due to arthritis [2, 3]. Patients with RA 
have significant disability; RA patients are 30% more likely to need help with 
personal care and twice as likely to have health-related activity limitation 
compared to people without RA [4]. Due to this burden, RA is expensive for 
patients, employers, family members, and governments—responsible for $39.2 
billion annual lost revenue [5].  
Biology of RA 
RA is an autoimmune disease that causes an inflammatory polyarthritis 
and most commonly affects the small joints of the hands and feet. There are 
several extra-articular organ systems affected by RA in addition to systemic 
effect [6]. The precise cause of RA manifestation remains unknown, but the 
pathogenesis and pathology of RA likely involve several complex immune 
pathways [6, 7]. These pathways, outlined in Figure 1, likely interact differently in 
patients making a single causative factor for RA still difficult to determine.   
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Figure 1. Overview of the biologic pathways involved in RA pathogenesis 
(Taken from [7]). 
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Generally, CD4+ T cells become activated after stimulation of a still 
undetermined antigen, perhaps elicited in genetically susceptible individuals after 
environmental factors, such as cigarette smoking or infection. These cells 
stimulate other immune and inflammatory cells and pathways, including the 
activation of cytokines, macrophages, and antibody-producing B cells [8].  
The major pro-inflammatory cytokines that are activated include Tumor 
Necrosis Factor-α (TNF-α), Interleukin-6 (IL-6), IL-7, IL-17 and vascular 
endothelial growth factor (VEGF). These pro-inflammatory cytokines cause 
numerous local and systemic effects that are outlined in table 1 [6]. All of these 
effects further amplify the inflammatory response occurring within the joints. 
Activated B cells are responsible for the production of autoantibodies 
related to RA. The two most commonly found antibodies in RA are rheumatoid 
factor (RF) and anti- citrullinated protein antibody (ACPA). If either antibody is 
present, a patient is referred to as having “seropositive RA.” However, about one-
third of patients with RA do not have detectable autoantibodies (termed 
“seronegative RA”) [7]. Other autoantibodies have been detected on research 
assays, but RF and ACPA are currently the only autoantibodies used clinically. 
Patients with RA do not typically acquire or lose RF or ACPA after diagnosis. 
Therefore, these tests are most helpful in diagnosis of RA and do not help 
measure disease activity. However, patients with seropositive RA typically have a 
more severe disease course, such as bone erosions, disability, extra-articular 
manifestations, and ongoing inflammation [9-11]. 
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As RA progresses, the CD4+ T cells recruit macrophages furthering the 
autoimmune process. The macrophages in turn upregulate osteoclasts to the 
 
Table 1:   Outline of the major cytokines that play a role in RA disease 
pathogenesis (Taken from [6]). 
 
synovial membrane, which destroys bone and leads to joint erosions and 
pathologic pannus formation. This process is mediated by macrophage colony 
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stimulation factor (MCSF) and the interaction of the receptor activator of nuclear 
factor kappa β (RANK) and RANK ligand (RANKL) [12]. Joint destruction is 
further enhanced by enzymes secreted by neutrophils, synoviocytes, and 
chondrocytes [7].    
 Several hallmark deformities have been described as being caused by 
RA due to bone and cartilage destruction. These include Boutonniere’s deformity, 
swan-neck deformity, hitchhiker’s thumb, and claw toe deformity [13]. Presence 
of these deformities is a marker of clinically advanced RA and is associated with 
increased morbidity and mortality. 
All of these complex pathways of inflammation cause elevation of serum 
inflammatory markers, such as erythrocyte sedimentation rate (ESR), and C-
reactive protein (CRP) during flares of RA such as synovitis in the small joints of 
the hands and feet [14]. ESR, a non-specific inflammatory marker, measures the 
rate at which red blood cells settle in one hour. CRP, another nonspecific 
inflammatory marker, is a protein that increases with inflammation in the body. 
Both of these blood tests are used clinically to detect active inflammation in a RA 
patient. However, flares and active disease may occur even with normal serum 
inflammatory markers, emphasizing the need to integrate other components to 
measure RA disease activity [14]. 
Classification of RA 
 Due to the complex nature of RA pathophysiology and unique 
manifestation and presentation of each RA patient, the American College of 
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Rheumatology (ACR) created sets of criteria to define RA and in doing so have 
created a benchmark to standardize patients included in RA research studies. 
These criteria also help differentiate RA from a number of diseases with similar 
symptoms but separate disease pathogenesis. These include the 1987 ACR and 
2010 ACR/EULAR criteria. The 1987 ACR criteria for the classification of RA, 
utilized clinical data and streamlined defining RA to having a minimum of 4 of 7 
criteria for at least 6 weeks in duration [15]. These criteria include: morning 
stiffness over an hour, arthritis of 3 or more joint areas, arthritis of hand joints, 
symmetric joint involvement, rheumatoid nodules, presence of rheumatoid factor 
in the serum, and radiographic changes such as erosions or periarticular 
osteopenia [15]. The combination of these criteria were chosen to optimize the 
specificity, selectivity, and overall accuracy of identifying a homogeneous 
phenotype of RA patients for use in research studies [15].  
 With advancements in scientific research for RA, the ACR and the 
European League Against Rheumatism (EULAR) created a new set of RA 
classification criteria in 2010. This criteria overhaul was mainly due to criticism 
that the 1987 criteria was not specific in detecting patients with early RA that did 
not have end-stage changes such as rheumatoid nodules and bone erosions. In 
addition, the 1987 criteria did not include ACPA testing which was described in 
the late 1990s to be much more specific than RF for diagnosing RA [16]. The 
2010 criteria include the number and type of joints involved, RA-related 
autoantibodies of RF and ACPA, acute phase reactants of ESR and CRP, 
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symptom duration, and uses a scoring system where a patient must score at 
least 6 out of 10 to be defined as having RA [16]. Both criteria exclude patients 
diagnosed with similar but separate diseases, such as psoriatic arthritis, systemic 
lupus erythematosus, and reactive arthritis. 
 In comparing the 1987 and 2010 criteria, both have strengths and 
limitations. The 2010 is more sensitive in detecting patients with early RA but 
undifferentiated forms of inflammatory arthritis may be incorrectly classified as 
RA when they later may develop another definable disease such as lupus, 
reactive arthritis, or psoriatic arthritis. The 1987 criteria has the opposite quality 
where patients with early RA may not be classified as RA despite significant joint 
involvement, disability, and pain [17]. Further, many options for RA treatment 
now exist and research suggests that the optimal time to initiate aggressive 
treatment is in the early phase of the disease in order to prevent late-stage 
findings such as erosions, nodules, and deformities and thus improve the long—
term quality of life and prevent disability for RA patients. Due to these opposing 
factors, both criteria are still used for research purposes. The 1987 and 2010 
criteria can be found outlined in Tables 2 & 3.  
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Table 2: 1987 ACR criteria for RA classification. Patients need at least 4 out 
of 7 criteria to be considered as having RA (Taken from [15]). 
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Table 3: 2010 ACR/EULAR criteria for RA classification. Patients need at 
least 6 points to be considered as having RA (Taken from [16]). 
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RA Disease Activity Measures 
 Once a patient is diagnosed with RA, a measure to determine the activity 
of RA is necessary to influence treatment decisions. Several RA disease activity 
measures have been created, as outlined in Table 4, to determine disease 
activity centered around a rating of patient perceived function, patient pain, 
patient global assessment, physician global assessment, number of tender joints 
swollen joints on physical examination, and ESR or CRP levels [18].  
 
  Table 4: Outline of the components of several RA disease activity 
measures according to the clinical signs and symptoms they assess.  
Taken from [18].  
 
 In 2012, the ACR recommended that clinical disease activity index (CDAI), 
disease activity score with 28 joints (DAS28), patient activity scale (PAS), routine 
assessment of patient index data (RAPID-3), and simple disease activity index 
(SDAI), as the five optimal measures for point-of-care RA disease activity 
measurement [19]. 
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 In comparing and contrasting these disease activity measures, DAS28 
with ESR or CRP is considered to be a strong measure for clinical practice and 
research because it includes both patient input and objective clinical findings, but 
is limited in clinical utility by the requirement for simultaneous laboratory, patient, 
and clinician measures that are time consuming and may not be able to be 
efficiently measured in all patients, particularly in typical clinical practice. Since 
laboratory measures are sometimes only obtained when there is a suspicion for 
flare, clinical use might bias towards patients with more active disease. The 
requirement of laboratory measures similarly limits the clinical use of SDAI. 
RAPID-3 and PAS are the easiest to be administered because they can be 
conducted, even remotely, by patient surveys, due to only requiring patient 
function and patient assessment surveys. However, both are limited since they 
are completely composed of subjective patient measures without clinician or 
objective input.  
The CDAI is an ideal combination of efficient use of clinician time and 
patient input without the requirement for laboratory measures. As discussed later, 
other factors, in particular obesity, may falsely elevate ESR and CRP, making 
CDAI a particularly ideal measure in a population that includes many obese 
patients. Including patient and physician global scores and a swollen joint count 
(SJC) and tender joint count (TJC) makes the CDAI an efficient and clinically 
relevant measure for assessing RA disease activity during patient appointments.  
Treatments for RA 
 12 
 
 Disease activity measures for RA allow clinicians an efficient and 
quantitative method for determining if treatments are effective by assessing 
changes in disease activity scores after initiating a treatment. In addition, disease 
activity measures have provided for an effective method to decide which of the 
numerous treatment options available are best to use based upon disease 
activity and severity.  
 Pharmacologic treatment options for RA span a wide range of drug 
classes, including nonsteroidal anti-inflammatory drugs (NSAIDs), 
corticosteroids, disease-modifying antirheumatic drugs (DMARDs) of which there 
are two subclasses: non-biologic DMARDs and biologic DMARDs [20, 21]. The 
ultimate goal of treatment for a RA patient is to “alleviate pain, restore patient 
quality of life, and ultimately, preserve their independence and ability to perform 
activities of daily living and vocational, and avocational pursuits” [22].  
NSAIDs have been a treatment option for RA over many decades. Their 
use is to relieve the symptoms of inflammation by inhibiting the enzyme 
cyclooxygenase important in the creation of prostaglandins which mediate 
inflammation and in turn which decreases joint swelling, tenderness, and pain 
[20]. NSAIDs are an inexpensive and widely available oral medication that can 
treat symptoms from inflammation quickly [23]. Negatively, NSAIDs have 
potentially serious gastrointestinal, renal, and cardiac side effects especially 
when used chronically in high doses such as RA patients often would need, and 
they do not modify the intrinsic disease process of RA. 
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Corticosteroids, such as prednisone, are fast-acting anti-inflammatory 
drugs that inhibit a multitude of inflammatory and immune system mediators [20]. 
Corticosteroids are very effective in quickly controlling an episode of RA flare, but 
are not preferred for long-term use since they have numerous side effects and 
also do not appreciably modify the disease process of RA [24]. In particular, 
corticosteroids have metabolic side effects such as weight gain so their use may 
indicate both disease activity and contribute to excess weight. Since 
corticosteroids work are fast-acting and effective for reducing inflammation, they 
are still commonly used despite the availability of many other options for RA 
treatment. 
The inception of DMARDs revolutionized the treatment of patients with RA 
by offering well-tolerated medications that could directly target RA pathways and 
halt the progression of disease with acceptable side effects [25]. The first 
DMARDs used were non-biologic DMARDs, that nonspecifically target T cells to 
suppress the immune system and decrease inflammatory processes [26]. 
Methotrexate is the standard of care for initial treatment of patients with moderate 
or severe RA. Methotrexate affects a multitude of inflammation pathways and 
cytokines including reduction of adenosine, dihydrofolate reductase, IL-2, IL-1, 
and IL-6 [27]. Other non-biologic DMARDs commonly used to treat RA are 
outlined in Table 5. 
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Biologic DMARDs revolutionized the treatment of RA by offering drugs that target 
a specific pathway in the pathogenesis of the inflammatory response related to 
RA typically using precisely targeted antibodies[7]. A list of d biologic DMARDs is 
shown in table 5. Biologic DMARDs powerfully reduce inflammation and prevent 
downstream consequences allowing many patients to live without deformities 
and disability as well as potentially decreasing morbidity and mortality. While the 
benefits may be powerful, biologic DMARDs can have serious side effects 
including fatal serious infections and are very expensive. In addition, since 
biologic DMARDs are antibodies, they cannot be given orally so have to be given 
by subcutaneous injection or intravenous infusion and may be inconvenient for 
patients. Also, biologic DMARDs have special storage requirements so may be 
unavailable to patients with low socioeconomic status or who live in developing 
countries. 
Table 5: Commonly used DMARD medications: Drug Name (Trade Name) * 
tofacitinib is a small molecule given orally that inhibits tyrosine kinase, but has 
targeted effects similar to biologic DMARDs. 
 
Non-Biologic DMARDs Biologic DMARDs 
Methotrexate (Rheumatrex) Etanercept (Enbrel) 
Sulfasalazine (Azulfidine) Adalimumab (Humira) 
Hydroxychloroquine (Plaquenil) Infliximab (Remicade) 
Leflunomide (Arava) Rituximab (Rituxan) 
Azathioprine (Imuran) Abatacept (Orencia) 
Mycophenolate mofetil (CellCept) Anakinra (Kineret) 
Mycophenolic acid (Myfortic) Tocilizumab (Actemra) 
Cyclosporine-A Certrolizumab pegol (Cimzia) 
Gold Golimumab (Symponi) 
D-Penicillamine Tofacitinib (Xeljanz)* 
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Non-Biologic Factors Affecting RA 
 Although the cause of RA is unknown, there are several factors that have 
been proven to play a role in disease incidence and ongoing activity. Studies 
investigating incident RA show that sex plays a significant role, with RA being 3-
fold more likely to occur in women [28]. Age also plays a significant role in RA 
incidence. Although total RA incidence is 41 out of 100,000 people in the US, this 
rate increases with age and peaks at ages 65-74 where overall incidence rates 
are 89.4 out of 100,000 people, nearly double the rate of all younger ages [1]. 
When this incidence is stratified by gender, the peak incidence rates for females 
are during ages 40-50 while male incidence peaks later in life, at age 70 [29]. 
This age gap of peak incidence suggests a sex or hormone related role in RA 
pathogenesis. Environmental factors have also been shown to both increase RA 
risk and also exacerbate disease activity. Smoking has been shown to greatly 
increase RA risk and also lead to worse disease outcomes. Smokers with over 
25 pack years of smoking have been observed to be over 3 times more likely to 
develop seropositive RA and more than two-fold likely to develop radiographic 
erosions [30]. In addition to smoking, socioeconomic status may have a profound 
effect on RA disease activity. In one study, low socioeconomic status showed to 
have an odds ratio (OR) of 3.3 ( [95% confidence interval [CI] 1.6, 6.7) for high 
disease activity when compared to RA patients with high socioeconomic status 
[31].  
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Obesity 
 Obesity, defined by the World Health Organization (WHO) as BMI over 30 
kg/m2, is a rapidly growing epidemic in the US [32]. Currently, 34.9% of adults 
age 20 years or older are obese in America [33]. This rampant problem is truly 
global as BMI has increased by 0.4 kg/m2 per decade over the past three 
decades [34]. Within the US from 2000 to 2010, the prevalence of people with a 
BMI over 30 kg/m2 increased from 19.8% to 27.2% alone [34]. The rapidly 
expanding waistline of the country has been also taking a toll on healthcare 
spending. In 2008, obesity related healthcare costs were estimated to be $147 
billion, nearly double that of 1998 [35]. Furthermore, obesity has been linked to 
increasing the disease burden in the population by raising the risk for chronic 
diseases including but not limited to hypertension, diabetes mellitus, and 
coronary artery disease in addition to RA [36].  
 Obesity consists of the over accumulation of white adipose tissue in the 
body, as an energy storage of triglycerides. White adipose tissue is an essential 
reservoir of fatty acid storage which is helpful for glucose regulation in times of 
energy depletion [37]. Adipocytes in white adipose tissue secrete adipokines [38] 
that are important in inflammatory pathways in the body by the production of IL-6, 
TNF-α, CRP, ESR, and monocyte chemoattractant protein 1 (Figure 2) [39]. It is 
hypothesized that adipokines mediate systemic inflammation and have distant 
organ specific effects, particularly the liver and muscle[40]. This forms a positive 
feedback loop in obesity that results in perpetual low-grade systemic 
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inflammation [39]. It is hypothesized, though not proven, that this inflammatory 
milieu from obesity may also contribute to systemic inflammation in obese 
patients with RA.  
Obesity and RA 
 Although it is accepted that obesity causes an increase in inflammatory 
pathway mediators, the exact biologic effects of obesity on RA is not fully 
understood. Several studies have shown associations between obesity and RA 
indicating that the two diseases likely affect each other. Obesity was associated 
with increased incidence of RA across men and women (OR 1.24 [95% CI 
1.01,1.53] compared to normal BMI) [41]. This association was even stronger 
among women in the Nurses’ Health Studies, with obese women under age 55 
[Hazard Ratio (HR) 1.65 (95%CI 1.34, 2.05)] having increased risk of later 
developing RA compared to normal and underweight women [42]. Meta-analysis 
of 11 studies that compared incidence of RA in obese versus non obese patients 
showed that obese patients had a relative risk of 1.25 (95%CI 1.07, 1.45) of 
developing RA compared to normal BMI [43].  
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Figure 2 Overview of the effects of obesity on inflammation. Taken from [39]. 
 Clinically, the association of obesity and RA has been shown through the 
observation of worse disease activity measures on obese patients as compared 
to normal weight patients, in several studies. Obesity has been associated with 
worsened measures of DAS28, modified health assessment questionnaire 
(MHAQ) (a survey that assessed a patient’s daily function), the clinical visual 
analog scale (a 0-10 scale of physician’s opinion of disease activity (VAS) and 
patient VAS) compared to normal BMI [44]. A study found that CRP and HAQ 
were significantly worse for patients that were obese compared to those with 
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normal BMI [45]. Another study found increasing continuous BMI to be positively 
correlated with DAS28 (r=0.34, p=0.001) [46]. Furthermore, obese patients with 
RA have a lower quality of life and less functional capacity, than patients with 
normal BMI [47]. Overall, these studies show that obesity may be associated with 
worsened RA disease measures. However, these studies were mostly performed 
in cross-sectional studies, so it is possible that patients with higher disease 
activity may be more likely to be obese due to decreased physical activity, 
medications such as corticosteroids, and a sedentary lifestyle. Additionally, 
clinically evaluating swollen and tender joints may be more difficult on obese 
individuals and obese patients typical complain of more tenderness which could 
be confused with RA disease activity [48]. Longitudinal, prospective studies 
evaluating the effect of obesity and weight change have not been reported. 
 In addition to the worsened disease activity measures in obesity, 
treatments for RA have been shown to be less effective among obese patients. 
Patients who were overweight and obese had 51% lower odds of being able to 
achieve low disease activity and 42% lower odds of achieving remission when 
compared to normal weight patients [49]. These results were again shown in 
another study where high BMI was independently associated with failure to 
achieve a DAS28 in the clinical remission category, on initial combination 
DMARD therapy with prednisone [50]. Anti-TNF medications may also be less 
effective in the obese population. Obese patients were significantly more likely to 
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have active disease compared to normal weight patients on Anti-TNF 
medications (OR 2.63 [95%CI, 1.31, 5.26]) [51].  
  Although obesity has shown to be detrimental to almost every aspect of 
RA including diagnosis, treatment, and outcomes, there is a paradox that obese 
patients have a protective effect on joint destruction in RA. This protective effect 
has been coined the obesity erosion paradox. BMI has been shown to be 
significantly inversely correlated with the Sharp-van der-Heijde score (used to 
assess radiographs for erosions and deformities) [52]. Assessing for erosions on 
a two-year MRI image follow-up, higher BMI was independently associated with a 
lower probability of progression of erosions [53]. A meta-analysis further showed 
the obesity erosion paradox on overall joint destruction: radiographic joint 
damage was negatively associated with obesity with a standardized mean 
difference of -0.15 (CI 95% -0.29, -0.02; p=0.03) [54]. The obesity erosion 
paradox suggests that obese patients with RA may have a more modifiable 
disease phenotype compared to patients with normal BMI. Some adipokines, in 
particular adiponectin, might paradoxically have anti-inflammatory effects in 
certain tissues, perhaps in the synovium though this is still controversial. 
 In total, research suggests that obesity negatively affects RA with the 
exception of the obesity erosion paradox. An important research question now is 
whether modifying weight also modifies many of the negative impacts of obesity 
on RA. Research on weight change in RA has been scarce, as most studies on 
obesity and RA evaluate obesity categories, comparing obesity and overweight 
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to normal BMI. One study conducted by Sparks et al, followed RA patients before 
and after bariatric surgery for weight loss [55]. In this study patients lost a mean 
of 41 kg twelve months after bariatric surgery. This significant weight loss 
correlated to decreased RA disease activity measures, less medication usage, 
and decreased serum inflammatory markers [55]. However, there was no control 
group and all patients lost weight through surgical intervention. Another 
prospective cohort study investigated typical weight gain and RA disease activity 
and found no significant association, but did not evaluate weight loss [44].  
 Since extreme weight loss due to surgical intervention showed significant 
improvements in RA disease activity, studies of typical weight change and RA 
disease activity are now necessary. We therefore aimed to investigate 
longitudinal weight change and its effects on ΔCDAI in RA patients.  
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OBJECTIVES 
 Studies have associated obesity with increased systemic markers of 
inflammation. Studies showed that obesity and overweight are associated with 
increased disease activity measures, higher medication use, and a lower 
probability of being able to reach remission or low disease activity states 
compared to normal BMI. The majority of these studies have found these 
associations in cross-sectional designs. Major weight change through surgical 
intervention has been shown to have a significant impact on RA disease activity 
and disease outcomes. There exists a gap in our understanding of whether 
typical weight loss may be a modifiable factor to improve RA disease activity. 
 This thesis seeks to describe the impact that typical weight change has on 
RA disease activity, as measured by CDAI. In addition, this paper seeks to 
describe if weight loss, defined by a significant decrease in BMI, will be 
associated with decreased CDAI measures. We hypothesize that a change in 
BMI will be associated with changes in CDAI measures. Specifically, we 
anticipate to observe that an increase in BMI will be associated with an increase 
in CDAI and a decrease in BMI will be associated with a decrease in CDAI.  
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METHODS 
Study Sample and Data Source 
We conducted a retrospective cohort study of RA patients who had two or 
more CDAI measures and corresponding BMI measures on the same dates 
using data from the electronic medical record (EMR). Patients with RA were 
identified by querying for patients with at least one International Classification of 
Diseases, Ninth Revision (ICD-9), a coding system used for billing and reporting 
purposes, for RA (714.0) in the Partners Research Patient Database Repository 
prior to 7/1/2014. We then identified patients that had at least two CDAI 
measures in the EMR. Medical record review determined RA according to either 
the 1987 ACR or 2010 ACR/EULAR criteria for RA to be included in this study. 
Patients that did not have at least two separate BMI measures within one week 
of each CDAI measure were excluded. Figure 3 shows a flow diagram illustrating 
the sample for analysis, all 178 subjects identified were seen at Brigham and 
Women’s Hospital for their rheumatology care.  
Data Collection 
 After identifying patients that qualified for the study, detailed medical 
record review was performed. The visit dates for medical record review was 
conducted as outlined in Figure 4. Each CDAI measure with corresponding BMI 
became the baseline visit date (T1), and then each sequential CDAI measure 
with a BMI measure was an additional visit. Each subject had at least two visit 
dates. At each visit date, sociodemographic, lifestyle, medication usage, 
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questionnaire data, RA characteristics, laboratory values, and comorbidities were 
collected.  
 
Figure 3: Flow diagram illustrating the analyzed study sample. ACR = 
American College of Rheumatology, BMI = body mass index, BWH = Brigham 
and Women’s Hospital, CDAI = Clinical Disease Activity Index, EULAR = 
European League Against Rheumatism MGH = Massachusetts General Hospital, 
RA = rheumatoid arthritis.  
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Figure 4: Schematic of data collection. T1 indicates the baseline visit date (first 
CDAI recorded with corresponding BMI). Each subsequent Tn are subsequent 
time points where CDAI and BMI were measured. Vertical lines coincide to time 
points where medical record review was performed to collect data on 
sociodemographics, lifestyles, medication usage, questionnaires, RA 
characteristics, laboratory values, and comorbidities. 
 
Primary Exposure 
 BMI was calculated as weight in kilograms divided by the square of height 
in meters (kg/m2). This was calculated from measured weights of subjects within 
one week of CDAI assessment (most often on the day of CDAI measurement). 
Since our study was over three years, we assumed that height would remain 
stable. The mode of the height was therefore used for each subject. Height was 
recorded in inches, and weight in pounds. We used the WHO classification of 
BMI, categories for underweight (<18.5), normal weight (18.5 to <25.0 kg/m2), 
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overweight (25.0 to <30 kg/m2), obese I (30.0 to <35 kg/m2), obese II (35.0 to 
<40 kg/m2), and obese III (BMI ≥40.0 kg/m2), to categorize BMI values at each 
visit. Additionally, subjects were categorized as being obese (BMI ≥30 kg/m2) or 
not obese (BMI <30 kg/m2). 
Outcome Measure 
 The outcome measure for this study was CDAI. CDAI is an ACR 
recommended RA disease activity measure that quantifies disease activity on a 
scale of 0-76 with validated cutoffs of ≤2.8 for remission, >2.8 to ≤10 for low 
disease activity, >10 to ≤22 for moderate disease activity, and >22 for high 
disease activity [19]. This measure was made available by an electronic tool for 
use in the EMR at BWH. This tool was available starting in 2012 for a quality 
improvement program to document disease activity for patients with at BWH. As 
part of this initiative, a research assistant at BWH was available to facilitate 
collection of patient-derived measures in order to limit the burden on the treating 
rheumatologist who performed clinically derived measures of global assessment 
and joint counts. 
CDAI is calculated by adding the swollen joint count (SJC), tender joint 
count (TJC), patient global assessment, and physician global assessment. SJC 
and TJC were derived from BWH rheumatologists palpating either 28 or 68 
individual joints that are shown in figure 5 making the official test either a CDAI 
(28) or CDAI (68). Patient global assessment and physician global assessment 
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are both subjective assessments of disease activity, rated on a scale of 0-10 with 
0 being none and 10 being the worst. 
 
 
Figure 5: Homunculus of 68 joints assessed in CDAI measures. Image of 
joints assessed in the CDAI for being swollen or tender. CDAI (28) includes all 
joints labeled in blue. CDAI (68 includes all joints labelled in blue and red.  
 
 In addition to the total CDAI score being recorded, we recorded the SJC 
and TJC counts. If a 68 joint count was taken by the physician this was recorded 
and also converted to a 28 joint count, so that every subject had a SJC and TJC 
count on the 28 joint scale. Additionally, patient and physician global 
assessments were collected. Lastly, for every CDAI measure, the wrists, 1st-5th 
metacarpophalangeal joints (MCP), 2nd-5th proximal Interphalangeal joints 
(PIP), and the interphalangeal joint of the thumb (IP) for the right and left hands 
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were recorded individually indicating if they were normal, swollen, tender or both 
tender and swollen.  
Covariates 
            In addition to the exposure and outcome data, we also collected covariate 
data at each visit, including sociodemographics, lifestyles, medication usage, 
questionnaire data, RA characteristics, laboratory values, and comorbidities. 
Most of the sociodemographic data were collected only at the baseline visit date, 
since these were unlikely to change during follow-up, with the exception of age, 
employment status, and health insurance which were collected at each time 
point. Age was collected as a continuous variable in years. Employment status 
was categorized as working, unemployed, retired, disabled, or student. Health 
Insurance was categorized as having private insurance, Medicare, Medicaid, or 
combinations. Sex was collected as a binary variable of being male or female. 
Education was categorized as less than high school (12th grade or lower), high 
school graduate (or equivalent), some college, college graduate, graduate 
degree, or unknown. Race was categorized as White, Black, Asian, or American 
Indian/Alaskan Native. Ethnicity was dichotomized as Hispanic/Latino or not 
Hispanic/Latino.  
 We collected lifestyle information on smoking status for subjects at each 
visit. Smoking was categorized as being a current, past, or never smoker at each 
visit. This was further dichotomized as ever or never being a smoker at each 
visit.  
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  Medication usage was collected at each visit. Biologic and non-biologic 
DMARDs were recorded based upon the specific DMARD that was being taken 
at the time of CDAI (listed in Table 5). Additionally, the methotrexate dosage (in 
mg/week) was recorded. Dosage and the specific type of corticosteroid was also 
recorded at each visit. Present medication usage at each visit was recorded for 
the following drug classes: NSAIDs, insulin, oral hypoglycemics (metformin, 
glyburide, and glipizide), statins, and opioids.  
 Questionnaire data specific to RA were recorded. The questionnaire data, 
which was part of the quality improvement project at BWH to increase validated 
measures of disease activity, included four components. While all patients in this 
study had CDAI measured, patients were not obligated to answer these 
additional questions, so these were only available in a subset. The Modified 
Health Assessment Questionnaire (MHAQ) score, which ranges from 0-2 with 0 
being fully functional and 2 being unable to do daily activities, [56]. The subject’s 
opinion of their disease activity over the past 6 months on a scale of 0-10, 10 
being the worst. The same question, but for their activity on the day of the 
appointment, and a 0-10 scale rating of their current level of pain. A question 
evaluating the experience of morning stiffness by the subject with possible 
responses of no morning stiffness, >30 minutes of stiffness, 1-2 hours of 
stiffness, 3-4 hours, and all day stiffness.  
 RA disease specific characteristics were also recorded at each time point, 
as outlined in Table 7. The RA diagnosis date was recorded to calculate the RA 
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disease duration from diagnosis to each visit. The presence of bone erosions 
was recorded based upon radiology reports from board certified radiologists. The 
presence of deformities was recorded from treating physician’s medical record 
notes. The presence of interstitial lung disease (ILD), an extra-articular RA 
disease manifestation, was recorded [57]. RA-related autoantibodies were 
recorded only once, as these tests are unlikely to change or be rechecked over 
time. The specific laboratory values for RF and ACPA were recorded in units/ml. 
These were dichotomized as positive or negative for RF and ACPA according to 
clinically accepted cutoffs. This was further categorized as being seropositive 
(positive for RF and/or CCP) or seronegative (negative for both RF and CCP). If 
a patient was referred to as being seropositive in medical record notes, this was 
recorded as being seropositive even if laboratory values were not available since 
these tests might have been performed at other institutions. 
 In addition to RA-specific laboratory values, other laboratory values were 
recorded at each visit. These included CRP, ESR, white blood cell counts, 
hemoglobin, hematocrit, platelets, hemoglobin A1c, creatinine, albumin, alkaline 
phosphates, alanine aminotransferase, aspartate aminotransferase, total 
bilirubin, low density lipoprotein, high density lipoprotein, triglycerides, and total 
cholesterol. These measures were recorded as clinically available. Since these 
were not checked on every patient at every visit, many patients had missing 
laboratory values. 
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 The presence of comorbidities was recorded at every visit. The 
comorbidities recorded included osteoarthritis (further categorized small joint, 
large joint, or spine), fibromyalgia, dyslipidemia, diabetes, coronary artery 
disease, chronic obstructive pulmonary disorder, depression, asthma, 
osteoporosis, hypothyroidism, hyperthyroidism, hypertension, stroke, cancer, 
chronic heart failure, peripheral vascular disease, chronic liver disease, 
gastrointestinal reflux disease (GERD) and chronic kidney disease. 
Statistical Analysis 
 We calculated descriptive statistics including frequencies, mean, median, 
range, interquartile range, and standard deviation among the entire study sample 
and also stratified by exposure status. We performed univariate tests to 
investigate whether sex, age, RA duration, smoking status, serologic status, and 
steroid usage were associated with the exposure and outcome, using t-tests for 
continuous normally distributed variables, Wilcoxon rank-sum tests for 
continuous non-normally distributed variables, chi-square tests for categorical 
variables, and Fisher’s exact tests for categorical variables with small cell sizes. 
These specific confounders were selected due to their previously defined 
significance of affecting RA disease activity in clinical studies [58-63].  
We used linear regression on the entire study population to assess 
whether ΔBMImin-max is associated with change in CDAI measures, and 
considered. Adjusted linear regression was further performed, adjusting for the 
above listed confounders, to test for the effects on the results. ΔBMImin-max was 
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determined by evaluating the clinical study visits with the maximum BMI 
observed and minimum BMI for each study subject. By doing this, we were able 
to standardize each subject to having only two study visits. In addition, we were 
able to quantify BMI change as positive or negative by subtracting the first 
chronological BMI taken by the second chronological BMI calculating a maximum 
ΔBMI for every patient. If the value was negative, it indicated that weight was lost 
between the two extreme weight visits, and if the value was positive weight was 
gained between the two extreme weight visits.  
The subject population was stratified into three groups, BMI loss, BMI 
stable, and BMI gain, unadjusted linear regression was used to test for a 
significance between ΔBMImin-max and change in CDAI within each of these three 
groups. BMI loss was defined as ΔBMI <-1 kg/m2, BMI stable was categorized as 
ΔBMI between -1 and 1 kg/m2, and BMI gain was categorized as ΔBMI >1 kg/m2. 
These categories and definitions were chosen due to them previously being 
defined as significant measures for BMI change by Baker et al [64].  Logistic 
regression was performed to evaluate whether BMI categories were associated 
with low or remission by CDAI, defined as a CDAI <10. From this odds ratios 
(OR) were calculated, as well as 95% CI.  
The data was analyzed using SAS 9.4® Software. A two-sided p value of 
<0.05 was considered statistically significant in all analyses. 
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RESULTS 
Descriptive Statistics 
We identified 178 RA subjects that met our inclusion criteria of having a 
minimum of two clinical visits where CDAI score and BMI was measured in the 
EMR. A total of 854 clinical visits were recorded from this sample, with a median 
of 5 clinical visits per subject, and a range of 2 to 11 clinical visits. Study visits 
included in these analyses occurred between 3/26/2012 and 5/29/2015. The 
mean age of at baseline study 60.2 years (standard deviation [SD] 13.5), 84.2% 
of subjects were female, and 84.2% were white, 55.0% had ever smoked, 50.6% 
had received a college or greater education, 45.5% were retired and 49.4% were 
on private medical insurance plan. The most common comorbidities were 
osteoarthritis 67.4%, hypertension 51.7%, and GERD 29.2% (Table 6). 
At the initial CDAI measure, the mean BMI was 28.4 kg/m2 (SD 6.25), with 
33.7% of subjects classified as underweight or normal, 34.3% of subjects being 
overweight and 32.0% of subjects being classified as obese. The mean RA 
duration was 11.9 years (SD 9.5) with 77.5% being seropositive, 53.4% having 
evidence of radiographic erosions and 14.6% having deformities from RA. The 
mean CDAI score was 13.6 (SD 11.1) with 6.7% of subjects in remission, 44.4% 
with low disease activity, 29.2% with moderate activity and 19.6% at high disease 
activity (Table 7).  
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Table 6 Subject sociodemographics, lifestyle factors, BMI, and 
comorbidities at baseline. The mean and standard deviation are defined for 
continuous variables, and frequency and percent are defined for dichotomous 
variables. GERD= gastroesophageal reflux disease, CAD= coronary artery 
disease, COPD= chronic obstructive respiratory disease. BMI obesity was 
classified as an BMI of >30kg/m2. BMI categories were classified by WHO 
classification of BMI, categories for underweight (<18.5), normal weight (18.5 to 
<25.0 kg/m2), overweight (25.0 to <30 kg/m2), obese I (30.0 to <35 kg/m2), 
obese II (35.0 to <40 kg/m2), and obese III (BMI ≥40.0 kg/m2). 
 
Characteristics of subjects at baseline (n=178) 
Variable 
Mean (SD) or 
N (%) 
Variable 
Mean (SD) or 
N (%) 
Sex  Comorbidities  
Female 150 (84.2%) Osteoarthritis 120 (67.4%) 
Age (years) 60.2 (13.5) Hypertension 92 (51.7%) 
Race  GERD 52 (29.2%) 
White 150 (84.2%) 
Hypothyroidis
m 
34 (19.1%) 
Non-White 28 (15.8%) Asthma 29 (16.3%) 
Education  Osteoporosis 27 (15.2%) 
Less than High school 3 (1.6%) Dyslipidemia 24 (13.5%) 
High school graduate 35 (19.7%) Diabetes 15 (8.4%) 
College or greater 90 (50.6%) CAD 15 (8.4%) 
Unknown 50 (28.1%) COPD 6 (3.4%) 
Work Status  
Smoking 
Status 
 
Working 90 (50.6%) Ever 98 (55.0%) 
Unemployed 2 (1.1%) Never 80 (45.0%) 
Retired 81 (45.5%) BMI (kg/m2)  
Disabled 5 (2.8%) Obese 57 (32.0%) 
Health Insurance  
BMI 
Classification 
 
Private 88 (49.4%) Underweight  1 (0.5%) 
Medicare 7 (3.9%) Normal  59 (33.2%) 
Medicaid 3 (1.7%) Overweight 61 (34.3%) 
Medicare and Private 
Insurance 
76 (42.7%) Obese I 35 (19.7%) 
Medicare and Medicaid 3 (1.7%) Obese II 13 (7.3%) 
Self Paid 1 (0.6%) Obese III 9 (5.0%) 
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 NSAIDs were used by 52.8% of patients, 17.4% used opioids, 31.4% were 
on steroids, 48.9% were on methotrexate, 14.6% were on other non-biologic 
DMARDs, 59.6% were on biologic DMARDs, and 87.1% were taking any 
DMARDs. Questionnaire data on the experience of morning stiffness was 
available for 97 patients at baseline with 18.5% reporting no morning stiffness, 
41.2% reporting morning stiffness of 30 minutes or less, 25.7% experiencing 
morning stiffness of 1-2 hours, 5.2% 3-4 hours and 9.3% having all day stiffness. 
MHAQ questionnaire data was available for 133 subjects at baseline with a mean 
score of 0.3 (SD 0.44) (Table 7). 
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Table 7: RA disease characteristics, disease activity measures and 
medication usage. The mean and standard deviation are defined for continuous 
variables, and frequency and percent are defined for dichotomous variables. 
CDAI scores were quantified by using 28 joint count CDAI assessment, and the 
score range was from 0-76. MHAQ was quantified on a 0-2 scale with 0 meaning 
no impairment on daily function and 2 being major impairment of daily function. 
Questionnaire data was quantified on a 0-10 scale with 10 being maximum 
activity or pain. and 0 being no activity or pain. ACPA = Anti Anti cyclic 
citrullinated protein, CDAI= clinical disease activity index, CRP= C-reactive 
protein, DMARDs= disease-modifying antirheumatic drug, ESR= erythrocyte 
sedimentation rate, ILD= Interstitial lung disease, RA=rheumatoid arthritis and 
RF= rheumatoid factor. 
RA characteristics at baseline 
Variable N 
Mean (SD) 
or N (%) 
Variable N 
Mean (SD) 
or N (%) 
RA Duration 178 11.9 (9.5) Bone erosions 178 95 (53.4%) 
Seropositive 178 138 (77.5%) Deformities 178 26 (14.6%) 
RF + 178 111 (62.4%) ILD 178 2 (1.1%) 
ACPA + 178 83 (46.6%) CDAI score 178 13.6 (11.1) 
Morning Stiffness    
CDAI 
Classification 
 
  
None 97 18 (18.5%) Remission (0-2.8) 178 12 (6.7%) 
< 30 minutes 97 40 (41.2%) 
Low Disease 
Activity (2.9-10) 
178 79 (44.4%) 
1-2 hours 97 25 (25.7%) 
Moderate Disease 
Activity (11-22) 
178 52 (29.2%) 
3-4 hours 97 5 (5.2%) 
High Disease 
Activity (>22) 
178 35 (19.6%) 
All day  97 9 (9.3%) MHAQ score 133 0.3 (0.44) 
Medication Usage   
Questionnaire 
Data    
NSAID's 178 94 (52.8%) 
Disease Activity 
Past 6 Months (0-10 
scale) 
45 4.64 (2.52) 
Opioids 178 31 (17.4%) 
Disease Activity at 
Appointment (0-10 
scale) 
45 4.47 (2.97) 
Steroids 178 56 (31.4%) 
Current Pain Today 
(0-10 scale) 
49 4.25 (2.99) 
Methotrexate 178 87 (48.9%) CRP (mg/L) 151 7.0 (10.4) 
Biologic DMARD's 178 106 (59.6% ESR (mm/hr) 43 23.8 (17.4) 
Non- Biologic 
DMARD's 178 26 (14.6%)      
Any DMARD usage 178 155 (87.1%)        
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Associations of ΔBMI with ΔCDAI 
 The primary hypothesis was to observe the effect that ΔBMI would have 
on ΔCDAI. Unadjusted linear regression was performed on all 178 subjects to 
analyze the overall trend within the sample population. For every 1 kg/m2 
increase in BMI, CDAI increased by 0.49, but these results were not statistically 
significant (p=0.155, 95%CI -0.176, 1.097). . No significant associations were 
found after adjusting for confounders including adjusting for sex, age, disease 
duration, smoking status, serologic status, and steroid usage. The change in BMI 
was observed to be non-significant as well with a β=0.493 (p=0.1264, 95%CI 
0.14, 1.12) (Table 8).  
Adjusted Linear Regression for ΔCDAI  
Variable β p value 95% Confidence Interval 
ΔBMI 0.493 0.126 -0.141 1.127 
Female -2.704 0.161 -6.495 1.087 
Age -0.083 0.139 -0.193 0.027 
RA duration 0.029 0.715 -0.126 0.183 
Smoking status 1.526 0.269 -1.188 4.241 
Seropositivity 2.424 0.147 -0.864 5.711 
Steroid Usage -1.507 0.315 -4.458 1.444 
 Table 8: Adjusted linear regression for ΔCDAI. All covariate data was based 
upon the baseline visit for each subject. Smoking status was quantified as a binary 
variable of ever being a smoke or never being a smoke. Steroid usage was 
quantified as taking any dosage of steroids at the baseline visit.  
 
 To further investigate the associations between ΔBMI and ΔCDAI, 
subjects were stratified into three groups, BMI gain, stable BMI, and BMI loss. 
Unadjusted linear regression was performed on these three models for ΔCDAI 
(Table 9).  
 38 
 
Stratified Unadjusted Linear Regression ΔCDAI 
Group n β p value 
95% Confidence 
Interval 
BMI loss 58 -2.606 0.028 -4.913 -0.298 
BMI stable 65 1.947 0.171 -0.863 4.756 
BMI gain 55 -0.053 0.956 -1.966 1.860 
Table 9: Unadjusted Linear Regression for ΔCDAI, Stratified by BMI gain, 
stable, loss. BMI gain=a positive ΔBMI >1, BMI stable= absolute ΔBMI <1, 
BMI loss=a negative ΔBMI >1. BMI=body mass index.  
  
A significant association was found in the BMI loss group with a β=-2.61 
(p=0.028, CI -4.91, -0.298). A scatter plot for this regression can be seen in 
Figure 6. To test the strength of the association found in the BMI loss group, 
adjusted linear regression was performed on this group adjusting for sex, age, 
disease duration, smoking status, serologic status, and steroid usage. The 
association remained significant with a β=-2.499 (p=0.044, CI -4.94, -0.061). 
Amongst those who lost >1 kg/m2, for every kg/m2 lost CDAI decreased by -
2.499. In the BMI stable and BMI gain groups, no significant association was 
found with β=1.945 (p=0.17, CI -0.863, 4.75) and β=-0.053 (p=0.956, CI -1.97, 
1.86), respectively. 
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Figure 6: Scatter plot of the unadjusted linear regression for BMI loss group.  
Table 10: Adjusted linear regression for ΔCDAI in the BMI loss group. All 
covariate data was based upon the baseline visit for each subject. Smoking 
status was quantified as a binary variable of ever being a smoke or never being a 
smoke. Steroid usage was quantified as taking any dosage of steroids at the 
baseline visit. BMI=body mass index. 
 
Adjusted linear regression for ΔCDAI among the BMI loss group (N=58)  
Variable β p value 95% Confidence Interval 
ΔBMI -2.499 0.044 -4.937 -0.061 
Female -6.846 0.064 -14.091 0.399 
Age -0.087 0.418 -0.302 0.128 
RA duration -0.118 0.550 -0.511 0.275 
Ever smoking 3.465 0.236 -2.341 9.272 
Seropositivity 1.322 0.713 -5.858 8.502 
Steroid use 0.986 0.769 -5.719 7.690 
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Associations of ΔBMI with Low/Remission Disease Activity 
 As a secondary analysis, we tested to see if BMI change was associated 
with a dichotomous variable of low/remission RA disease activity, as defined by a 
CDAI score <10 at the later clinical visit used in the BMImin-max analysis. 
Unadjusted logistic regression was performed on all study subjects for ΔCDAI. 
The results were not statistically significant with an OR 0.990 (95% CI 0.855, 
1.146).  
The subjects were further stratified into the BMI gain, stable, and loss 
groups as defined above for the linear regression model. Unadjusted logistic 
regression was performed on all three stratified groups to evaluate if BMI change 
within these groups was associated with low/remission RA disease activity. The 
BMI loss group were less likely to achieve low or remission RA disease activity 
with an OR 0.882 (95%CI 0.363, 2.139), but these results were not statistically 
significant. No significant associations were found in the BMI gain or stable 
groups (Table 10). 
Unadjusted Logistic Regression for Low/Remission Disease 
Activity 
Group N OR 95% Confidence Interval 
BMI Loss 58 0.882 0.363 2.139 
BMI Stable 65 0.995 0.658 1.503 
BMI Gain 55 1.452 0.92 2.293 
Table 11: Unadjusted logistic regression for ΔCDAI as a predictor for low or 
remission RA disease activity. RA disease activity of low or remission was 
defined as a CDAI <10 at the second clinical visit used in the BMI min-max 
analysis. BMI=body mass index, OR=odds ratio.  
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DISCUSSION 
 We showed that in patients with RA that lost weight were significantly 
associated with decreased RA disease activity as measured by CDAI, in the 
routine clinical setting. For each BMI point lost above 1 kg/m2, CDAI decreased 
by 2.499 per kg/m2 independent of sociodemographic and RA characteristics. 
These results build on prior literature that showed that obesity is associated with 
worsened RA disease activity measures in cross-sectional designs. Our results 
are consistent with a longitudinal study that showed significant improvements in 
RA disease activity and RA disease outcomes when weight loss was achieved 
through surgical interventions. This is the first longitudinal study to demonstrate a 
significant relationship between weight loss and disease activity in the typical 
clinical setting. 
Summary of Results 
 Descriptive statistics recorded at baseline allowed us to make several 
generalizations about the study population utilized in this paper. The population 
was primarily comprised of late-middle aged, white, females, with the majority 
receiving higher education and having medical insurance, which is typical of RA 
patients seen at BWH. With regards to RA, the subjects had primarily 
longstanding RA, were seropositive, were taking a DMARD, many had 
radiographic erosions, and had disease activity quantified by CDAI mostly in the 
low to moderate range. All of these sociodemographic and RA disease 
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characteristics at baseline were similar to the baseline characteristics seen in a 
study that measured CDAI from Consortium of Rheumatology Researchers of 
North America (CORRONA), a prospective observational United States research 
registry of patients with RA [65]. This indicates that our study population may be 
generalizable to other RA populations.  
By stratifying into groups of BMI gain, stable, and loss, we were able to 
observe that a BMI loss of greater than 1kg/m2 was significantly associated with 
a decrease in CDAI measures, for both unadjusted and adjusted linear 
regression models. No significant association was found within the BMI stable 
and gain groups. The observation of no significant association in the BMI gain 
group is consistent with a previous study [44]. This indicates that weight loss may 
be a more important factor for affecting disease activity compared to weight gain. 
This finding shows promise that weight loss may be a potential intervention for 
RA patients. However, we were unable to record whether weight loss was 
intentional, we did not have data on diet and physical activity. We were able to 
record comorbidities at the time of study visits but it is possible that undiagnosed 
chronic diseases such as cancer might have influenced weight loss. We did have 
rich data available on other potential confounders, such as age, sex, education, 
insurance, RA duration, serostatus, bone erosions, smoking, steroid usage, and 
DMARD usage. Our results remained significant after adjustment for these 
variables, arguing that the effect of residual confounding from unmeasured 
factors was minimal. 
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Lastly, in analyzing changes in BMI as a predictor for low or remission RA 
disease activity, no significant associations were found using logistic regression. 
Logistic regression models were repeated on the study sample stratified by BMI 
gain, stable, and loss categories and no significant predictive association was 
found for any of the groups. From this, our study cannot say whether or not 
weight change can predict changes to clinically meaningful disease activity 
categories. One possibility is that our study was underpowered to find a true 
association in the logistic regression analysis. Prior studies have shown that 
overweight and obese had 51% lower odds of being able to achieve low disease 
activity and 42% lower odds of achieving remission when given comparable 
treatments to normal weight patients [49]. A larger study would be necessary to 
see if weight change can also have an impact on disease activity categories.  
Strengths and Limitations 
 The major strength of the study sample analyzed in this paper was the 
availability of multiple CDAI measures in the routine clinical setting. Specifically, 
finding a study sample of this size retrospectively with a minimum of two CDAI 
measures with correlating BMI measures was a significant task. RA disease 
activity measures in general and specifically CDAI are typically used to quantify 
RA disease activity for research studies, and are not routinely collected and 
recorded for clinical visits. Rather, RA disease activity is typically described 
qualitatively. When CDAI is recorded for typical clinical use it is typically used for 
patients switching medications to quantify the effectiveness of the new 
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medication so it is possible that CDAI clinical visits occurred when patients had 
active disease. However, we were also able to quantify medications changes in 
this study. Another factor enabling this study was the effort made by BWH to 
increase the use of clinical disease activity measures recorded in EMR for RA 
patients. In this effort, a research assistant was provided to the rheumatology 
physicians to assist in collecting and recording this data. Therefore, the study 
sample may have occurred randomly since patients often agreed to have CDAI 
performed in the waiting room prior to evaluation by the rheumatologist. In future 
studies, we will be able to adjust for medication changes.  
 Additionally, it is possible that the study sample may not be generalizable 
to the general population of patients with RA. Specifically, this sample was 
collected at BWH, a single center private tertiary care medical institution, and the 
majority patients in this study were educated and almost all had health insurance 
and were older, and mostly white. With regards to RA, the subjects had 
longstanding RA and most had elevated disease activity. Many had seropositive 
RA with bone erosions and deformities. Our study therefore requires replication 
in larger studies in diverse patient populations.  
 The significant association between ΔBMI and ΔCDAI in the BMI loss 
group may have important clinical implications. For patients with RA, changing 
their lifestyle to lose weight could provide relief in RA disease activity. Physicians 
have the potential to add weight loss as an intervention they promote to patients 
for RA disease activity rather than the other known benefits of reducing weight. 
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However, we did not find a significant association between weight loss and RA 
remission/low disease activity, so it is not clear whether our results are clinically 
meaningful. Further studies in our dataset will evaluate absolute weight loss, 
weight loss trajectories, and will incorporate repeated measures to further 
explore this relationship. 
All of the other statistical tests performed found results that were not 
statistically significant. These studies may have been underpowered to detect a 
true association, but it is also possible that our significant finding was biased, 
confounded, or due to multiple comparisons. However, we pre-specified this 
analysis based on prior literature and had rich covariates available for adjustment 
in multivariable analyses. It is possible that CDAI visits may have systematically 
occurred in patients with higher disease activity, however a research assistant 
approached patients randomly and disease activity in our sample was similar to 
other RA cohorts. A larger study is necessary to replicate the significant 
relationships that we report and to investigate other outcomes related to weight 
loss and disease activity.  
Length of follow-up was another limitation of this study. All of the clinical 
visits recorded in this study were taken over a three-year period, and the mean 
follow-up on each individual subject was 21.6 months. This left a relatively limited 
window of time that significant weight change could be observed. A prospective 
study that follows subjects over a longer time period would be able to control for 
periodic changes of weight by showing longstanding maintained weight change. 
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Additionally, BMI may not accurately reflect individual’s body composition and 
other measures such as waist/hip ratio, body shape, and adiposity were 
unavailable. In addition, measured of physical activity, diet, and intention to lose 
weight were unavailable. Future prospective studies with longer follow-up that 
include these measures would strengthen the association between weight loss 
and improved RA disease activity. 
Future Studies 
 Overall, the significant results found in this study are promising, but further 
analysis of the dataset used for this thesis and future studies analyzing the 
association of weight change and RA disease activity measures are necessary to 
completely understand this relationship.   
 Currently, the data collected for this thesis are being further analyzed so 
that the relationship between changes in BMI and CDAI can be better 
understood. Time of follow-up between visits is being standardized. By doing 
this, we will be able to better understand if the rate of weight loss is affecting the 
results. Current research indicates that rapid weight loss is associated with worse 
RA outcomes, and in general with serious medical issues [64]. Therefore, our 
further analysis plans to account for these factors. Additionally, medication usage 
and changes in medication regimens are being analyzed for the creation of 
propensity scores to control for medication usage being a major factor for 
disease activity changes. With further analysis, and by controlling for time and 
medication changes, other significant relationships between weight change and 
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disease activity may be found. A relationship between specific DMARDs, 
steroids, dosage of steroids, dosage of methotrexate can be observed in their 
relation to disease activity and weight change. In addition, we will use advanced 
statistical methods accounting for repeated measures to fully utilize the strength 
of the data collected. We will also classify patients according to weight loss and 
CDAI trajectories to understand the time-varying course of both measures. 
 Beyond this study, it will be essential to conduct similar research on larger 
samples powered to investigate the relationship between BMI exposures and RA 
disease activity outcomes. An ideal candidate for this future study is the Brigham 
Rheumatoid Arthritis Sequential Study (BRASS). BRASS is a prospective 
observational single-center cohort of over 1,400 RA patients at BWH. These 
patients undergo yearly research study visits where detailed laboratory measures 
and disease activity measures are taken [66]. Rich phenotypic data on functional 
status, physical activity, medications, and behaviors are routinely collected. In 
addition, subjects answer questionnaires every six months to provide interim 
data. Follow-up up to 13 years is available in BRASS. This cohort therefore has 
all these measures readily available and would allow for a similar analysis as 
done in this paper to be conducted on a larger sample albeit with measures 
taken in the research setting, instead of in the real world clinical setting as in this 
analysis. 
 If the results found in this paper can be replicated, it will be necessary to 
initiate new observational and interventional studies. Specifically, prospective 
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studies of larger patient populations will lead towards having more power to 
detect true associations and more refined, prospective measures of 
anthropometrics, metabolic factors, diet, and physical activity. Analyzing the 
change in body fat composition would be crucial to furthering the understanding 
of how specific changes in body composition affect RA disease activity 
measures. These studies would have physiologic implications that different body 
tissues are having on RA disease activity, and could ultimately lead to weight 
loss becoming a clinical intervention for RA patients.  
Currently at BWH, clinical researchers are preparing for an intervention 
based clinical trial on weight loss and RA disease activity. By conducting a 
randomized controlled trial that observes weight change and RA disease activity 
unmeasured confounding can be adequately addressed and translational studies 
measuring changes in systemic inflammation and adipokines can also be 
performed.  
Conclusions 
 We observed that weight loss occurring in the typical clinical setting was 
associated with improved RA disease activity. These results may have important 
implications for patients, clinicians, and researchers. Further studies analyzing 
this relationship are necessary to replicate these results. In the future, weight 
loss intervention studies are necessary to determine the relationship between 
weight loss and RA disease activity. 
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